DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of ...
The US Food and Drug Administration (FDA) has approved a once-daily treatment with netarsudil and latanoprost ophthalmic solution (Rocklatan, Aerie Pharmaceuticals) to decrease elevated intraocular ...
A novel contact lens-based system, which uses a strategically placed drug polymer film to deliver medication gradually to the eye, is at least as effective, and possibly more so, as daily latanoprost ...
A total of 18 patients with glaucoma were given either fixed-dose Roclatan or its individual components Aerie Pharmaceuticals announced topline data from the Mercury 1 study, a Phase 3 trial ...
IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...
Fort Lauderdale, Florida (May 8, 2002) – Switching to XALATAN® (latanoprost ophthalmic solution) once daily from monotherapy with other medications, including prostaglandin derivatives, for open angle ...
Thea Pharma’s work to eliminate preservatives from latanoprost formulations has landed it an FDA nod in open-angle glaucoma and ocular hypertension, clearing the company to launch a differentiated ...
Peapack, New Jersey (May 2, 2002) - Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback